Skin lightening regimens follow 1-3 weekly sessions during the 4-8 week intensive phase

It is classified as a research chemical, meaning: It cannot be legally marketed as a drug or supplement It is not recognized as "Generally Recognized as Safe" (GRAS) No New Drug Application (NDA) has been submitted It has not undergone the formal FDA approval process Research Chemical Status BPC-157 is available for purchase as a "research chemical" in most jurisdictions, with important caveats: Sold for "research purposes only" Not for human consumption (legally) No quality standards enforced by regulatory agencies Purity and identity depend entirely on supplier integrity International Regulations Regulatory status varies by country: United States : Research chemical, not approved for human use European Union : Not approved, status varies by member state Canada : Not approved for human use, research chemical Australia : Not approved, TGA Category 4 substance United Kingdom : Not approved for human use Sports and Competition BPC-157 is not specifically listed on the World Anti-Doping Agency (WADA) prohibited list, unlike TB-500

Its important for users to follow the recommended usage instructions and to consult with a dermatologist to ensure safety and effectiveness, as some ingredients might cause skin irritation or other side effects when used improperly
Because angiogenesis is a defining hallmark of tumor growth and metastatic progression, any therapeutic agent that enhances neovascularization could, in theory, facilitate tumor expansion and promote metastatic dissemination